In regards to news this month on the Mash mice, there’s a
In regards to news this month on the Mash mice, there’s a very real possibility that they chose not to release it yet due to ongoing discussions related to why they pulled the abstract right after approval. The same reason they might have pulled the abstract (a partner getting serious who doesn’t want others seeing results and/or an opportunity to slip into their negotiations and put their plans at risk) is the same reason they may have those January estimated results and haven’t shared them. Not only are these other two trials similar to the first, but they’re actually even more important as they can help us expand our inflammation efforts and also tie us to GLP-1 drugs, which happen to be the hottest ticket in town.
So while I’d love to hear about the results, I anticipate hearing about a Mash partner before we do the Mash mice. I don’t think we’ll have to wait too long, to be honest.
#Strategery
27
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
The Growth of the Dry Type Transformer Market The global dry type transformer market is set to experience substantial growth, projected to rise from an estimated USD 11.72 billion in the near future to USD 16.33 billion by the end of the decade. This growth is fueled by a rising demand for reliable, sustainable, and low-maintenance power distribution solutions across...
Continue Reading
GuideWell Unveils Its 2024 Impact Report Focused on Health Care GuideWell Mutual Holding Corporation recently published its annual Impact Report, shedding light on the organization's significant advancements in health care accessibility and quality. This not-for-profit entity is dedicated to reshaping how health services are delivered while putting its members and...
Continue Reading
Enhancing Automotive Security with Drones In a significant advancement for automobile dealerships, Titan Protection and Consulting has successfully implemented its innovative security drone technology. This unprecedented deployment focuses on curbing theft and enhancing surveillance at automotive retail facilities. With the rise of sophisticated security solutions,...
Continue Reading
Atossa Therapeutics to Join the 2024 Maxim Healthcare Summit SEATTLE — Atossa Therapeutics, Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company committed to developing innovative solutions in oncology, has exciting news to share. The company has announced that Michael Parks, the Vice President of Investor and Public Relations, will take part in a virtual...
Continue Reading
Investors Advised to Act Swiftly in Vicor Class Action Lawsuit Attention investors! If you've lost over $100,000 in Vicor Corporation shares, now's the time to take action. Kahn Swick & Foti, LLC (KSF), along with managing partner Charles C. Foti, Jr., a former Attorney General of Louisiana, wants to remind you of an important deadline approaching for filing lead...
Continue Reading
